Prosecution Insights
Last updated: April 19, 2026

Editas Medicine Inc.

13 pending office actions

Portfolio Summary

13
Total Pending OAs
6
Final Rejections
7
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18537754 SELECTION BY ESSENTIAL-GENE KNOCK-IN HILL, KEVIN KAI 1638 Non-Final OA Dec 12, 2023
18161806 COMPOSITIONS AND METHODS FOR TREATING CEP290 ASSOCIATED DISEASE KELLY, ROBERT M 1638 Non-Final OA Jan 30, 2023
18059213 SYSTEMS AND METHODS FOR TREATING ALPHA 1-ANTITRYPSIN (A1AT) DEFICIENCY CHONG, KIMBERLY 1636 Non-Final OA Nov 28, 2022
17786753 ENGINEERED CELLS FOR THERAPY GONZALES, JOSEPHINE MARIA 1631 Non-Final OA Jun 17, 2022
17836165 OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS MONTANARI, DAVID A 1632 Final Rejection Jun 09, 2022
17757069 MODIFIED CELLS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES SPENCE, JENNIFER SUZANNE 1633 Final Rejection Jun 08, 2022
17666390 CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE DHAR, MATASHA 1632 Non-Final OA Feb 07, 2022
17572403 CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS SINGH, ANOOP KUMAR 1632 Final Rejection Jan 10, 2022
17533007 EVALUATION OF CAS9 MOLECULE/GUIDE RNA MOLECULE COMPLEXES LEITH, NANCY J 1636 Final Rejection Nov 22, 2021
17433975 CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP) SULLIVAN, STEPHANIE LAUREN 1635 Non-Final OA Aug 25, 2021
17430382 MODIFIED NATURAL KILLER (NK) CELLS FOR IMMUNOTHERAPY GRABER, JAMES J 1631 Non-Final OA Aug 12, 2021
16474198 SYNTHETIC GUIDE MOLECULES, COMPOSITIONS AND METHODS RELATING THERETO VYAS, KEYUR ANILKUMAR 1637 Final Rejection Jun 27, 2019
16098464 CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY TINSLEY, BRENDAN THOMAS 1634 Final Rejection Nov 02, 2018

Managing Editas Medicine Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month